Management ChangeMay 6, 2026, 09:51 AM
Actuate Therapeutics Appoints Martin H. Huber, MD, to Board
AI Summary
Actuate Therapeutics, Inc. announced the appointment of Martin H. Huber, MD, to its Board of Directors, effective May 1, 2026. This appointment expands the Board from seven to eight directors. Dr. Huber, an industry veteran with extensive experience in oncology drug development, will serve as a Class III director and on the Nominating and Corporate Governance Committee. He will receive an initial grant of 30,000 stock options, an annual retainer of $44,000, and a quarterly consulting fee of $3,000.
Key Highlights
- Martin H. Huber, MD, appointed to Actuate Therapeutics' Board of Directors, effective May 1, 2026.
- The Board of Directors expanded from seven to eight members with Dr. Huber's appointment.
- Dr. Huber will serve as a Class III director until the Company's 2027 annual meeting of stockholders.
- He will serve on the Nominating and Corporate Governance Committee of the Board.
- Dr. Huber will receive an initial grant of 30,000 non-statutory stock options.
- His annual retainer will be $44,000, paid in equal quarterly installments.
- A separate consulting agreement provides Dr. Huber with a quarterly fee of $3,000 for R&D advisory services.
- Dr. Huber previously served as President and CEO of Mersana Therapeutics from 2023 to January 2026.
Price Impact
More from ACTU